NASH Drug Treatment in 2025: What’s Approved, What Works, and What’s Available in Pune

For two decades, patients with NASH heard the same answer when they asked about medication: there is nothing approved. Change your diet. Lose weight. Wait.

That answer changed in 2024  and the field of liver disease has not looked the same since. The first drug specifically approved for NASH is now a clinical reality, a wave of additional agents is behind it, and for patients in Pune and across India, understanding what this means for their care is more important than ever.

For specialist guidance on NASH approved drug treatment Pune, Dr. Bipin Vibhute  Liver and Multiorgan Transplant Surgeon  provides comprehensive hepatology management at thelivertransplant.com, helping patients understand both the new pharmacological options and the stage-specific decisions that determine whether they are eligible.

Key Takeaways :

• Why NASH had no approved drug for over 20 years  and what changed
• What resmetirom is, how it works, and what the clinical trial data actually showed
• Which patients are eligible  and why fibrosis staging matters before starting treatment
• What Indian patients should know about drug availability and current management options
• What the treatment pipeline looks like  and why combination therapy is the direction of travel

Why Did NASH Have No Approved Drug for So Long?

More than 30 drugs failed in NASH clinical trials before the first approval in 2024. This was not a failure of investment or effort  it was a failure of biological understanding that took two decades to resolve.

NASH as a Multi-Pathway Disease

NASH is not caused by a single mechanism. It involves simultaneous fat overload, oxidative stress, hepatic inflammation, mitochondrial dysfunction, and progressive fibrosis  all operating at different intensities in different patients.

Early drug development targeted one pathway at a time. Antioxidants reduced oxidative stress while inflammation continued. Anti-inflammatory agents reduced immune activity while fat accumulation and fibrosis persisted. 

Each drug succeeded in its specific target while the overall disease progressed through unaddressed pathways.

To understand why the population at risk is so large in India in particular  and how dietary and metabolic patterns compound the multi-pathway nature of this disease  4 Reasons Why Indians Are at Radar of Fatty Liver provides important context. 

The liver simply had too many ways to continue scarring for any single-mechanism drug to stop it comprehensively.

What the Failures Taught Researchers?

Paradoxically, the failed trials provided the mechanistic clarity that eventually led to success.

They established that histological endpoints  actual tissue changes on liver biopsy  were necessary to prove efficacy. 

They identified the patient population most likely to respond: those with active inflammation and fibrosis at F2–F3, before irreversible cirrhosis. And they refined the understanding of which pathways were most central to disease progression.

Resmetirom succeeded where others failed partly because it targeted hepatic metabolism at the level of fat processing itself, rather than downstream consequences.

What Is the First Approved NASH Drug  and How Does It Work?

Resmetirom (Rezdiffra)  The FDA Approval

In March 2024, the US Food and Drug Administration granted accelerated approval to resmetirom, sold under the brand name Rezdiffra, for the treatment of adults with NASH who have moderate-to-advanced liver fibrosis (F2 or F3 staging), to be used alongside diet and exercise.

This was the first pharmacological agent ever specifically approved for NASH  a milestone the hepatology community had been working toward for over two decades.

How a Thyroid Receptor Drug Helps the Liver

Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist. This means it activates a specific thyroid hormone receptor found predominantly in the liver, without the cardiovascular and bone-related effects of whole-body thyroid hormone stimulation.

Thyroid hormone receptor beta activation in the liver does three clinically relevant things:

It increases the liver’s capacity to oxidise (burn) fatty acids  reducing fat accumulation directly at the cellular level. It reduces the production of VLDL cholesterol  the fat the liver exports into the bloodstream. And it reduces hepatic inflammatory and fibrotic signalling  targeting two of the downstream consequences of fat overload simultaneously.

In plain language: resmetirom helps the liver process and eliminate fat more efficiently while reducing the inflammation and scarring that cause progressive damage.

This mechanism  acting directly on hepatic metabolism rather than on downstream inflammatory pathways  is why resmetirom succeeded where many earlier anti-inflammatory or antioxidant approaches did not.

What the MAESTRO-NASH Trial Actually Showed?

The pivotal trial  MAESTRO-NASH  was published in the New England Journal of Medicine and enrolled 966 patients with biopsy-confirmed NASH and F2–F3 fibrosis.

At 52 weeks, the results at the 100mg dose were:

NASH resolution (no active steatohepatitis on biopsy) achieved in 29.9% of resmetirom patients versus 9.7% on placebo. Fibrosis improvement (at least one stage reduction) in 25.9% versus 14.2% on placebo.

What do these numbers mean for a patient?

Roughly 1 in 3 patients on resmetirom achieved histological NASH resolution  meaning the active inflammation had completely cleared on biopsy. Roughly 1 in 4 had measurable reversal of liver scarring.

These are not dramatic numbers, but they are clinically meaningful  and they represent a real pharmacological benefit in a disease that previously had none.

Who Is Resmetirom Actually For  and Who Is It Not For?

This is the question most patient-facing content does not answer clearly  and it matters enormously for clinical decision-making.

The F2–F3 Fibrosis Requirement

Resmetirom is approved specifically for patients with NASH and F2 (moderate) or F3 (advanced but pre-cirrhotic) fibrosis. It is not indicated for F0–F1 (mild or no fibrosis) where lifestyle change alone is the primary intervention.

It is not indicated for F4 fibrosis (cirrhosis). By the time NASH has progressed to cirrhosis, the structural liver damage is beyond what this drug’s mechanism can address.

Understanding how fibrosis develops and how each stage is classified helps clarify exactly why this window exists  Fibrosis of the Liver explains the F0–F4 grading system and what the scarring process means for long-term liver function. 

This creates a specific clinical urgency: patients who suspect they have NASH need to have their fibrosis accurately staged  through FibroScan, FIB-4 calculation, or biopsy  to determine whether they are in the eligible window.

A patient who is currently at F3 and does not receive treatment may progress to F4 cirrhosis and lose eligibility. The window of opportunity is real and time-sensitive.

The Lifestyle Requirement Is Non-Negotiable

The FDA approval explicitly requires resmetirom to be used alongside diet and exercise  not instead of them. The MAESTRO-NASH trial was conducted in patients who were also managing their lifestyle.

A patient who takes resmetirom but continues an unrestricted high-fructose, high-fat diet with no physical activity will have suboptimal results. The drug is a meaningful adjunct to lifestyle change, not a replacement for it.

What Drugs Are Doctors Using for NASH Right Now?

Before and alongside resmetirom, experienced hepatologists have been using several evidence-supported agents for NASH  particularly relevant for Indian patients where resmetirom availability is still developing.

Semaglutide  The Nuance Most Patients Miss

Semaglutide  the GLP-1 receptor agonist used for type 2 diabetes and obesity  generated significant excitement in NASH when its phase 2b trial (NEJM 2021) showed 59% NASH resolution versus 17% on placebo.

However, this headline number requires important context. Semaglutide showed excellent NASH activity reduction (inflammation, cell injury) but did not achieve statistically significant fibrosis improvement in this trial.

Improving NASH activity is not the same as reversing scarring. The larger phase 3 ESSENCE trial results will clarify whether semaglutide achieves the fibrosis endpoints needed for a broader NASH indication.

In current Indian practice, semaglutide is a reasonable choice for NASH patients with concurrent obesity or type 2 diabetes  where both the metabolic and liver activity benefits are supported by evidence.

Pioglitazone  Solid Evidence in Diabetes-Related NASH

Pioglitazone (a thiazolidinedione insulin sensitiser) has the most established histological evidence among older agents  the PIVENS trial showed reduced liver inflammation and fibrosis in NASH patients with type 2 diabetes.

It is a reasonable first-line pharmacological addition for NASH patients with concurrent insulin resistance or type 2 diabetes who cannot tolerate GLP-1 agonists, with awareness of weight gain and fluid retention as side effects.

Vitamin E  Selected Patients Only

Vitamin E (800 IU daily) has evidence for histological improvement in non-diabetic, non-cirrhotic NASH  the PIVENS trial demonstrated benefit in this specific subgroup.

Long-term high-dose use carries concerns (potential prostate cancer risk signals in men; possible all-cause mortality signal at very high doses), limiting its broad application.

It remains a reasonable option for younger, non-diabetic NASH patients with mild-to-moderate fibrosis who are not candidates for other agents.

For a fuller picture of how vitamins and antioxidants fit within the NASH treatment framework, Role of Vitamins for NASH Treatment provides useful clinical context on when and for whom these agents are appropriate. 

SGLT2 Inhibitors  Emerging Evidence

Empagliflozin, dapagliflozin  primarily used for type 2 diabetes and heart failure  are showing early promising signals in NASH: reduced liver enzymes, reduced hepatic fat on MRI, and modest inflammatory marker reduction.

They are not yet approved specifically for NASH but represent an emerging area. For NASH patients who also have diabetes, heart failure, or chronic kidney disease  where SGLT2 inhibitors are already indicated  their concurrent liver benefit is clinically relevant.

What Does the Drug Pipeline Look Like for NASH?

The NASH drug pipeline is one of the largest in all of medicine  over 50 compounds in various stages of development at the time of writing.

Why Combination Therapy Is the Direction of Travel?

The mechanism insight that resmetirom’s development provided is being applied to combination approaches. Trials combining resmetirom with GLP-1 agonists are underway, targeting hepatic metabolism (resmetirom) and systemic metabolic factors (GLP-1) simultaneously.

Most hepatology experts now expect that the optimal NASH treatment will look like a combination regimen  similar to how HIV and hepatitis C are managed  rather than a single agent.

FXR Agonists  A Complicated Story

Obeticholic acid (OCA)  a farnesoid X receptor agonist  was one of the most anticipated NASH drugs. It showed significant fibrosis improvement in the REGENERATE trial but failed to receive standard FDA approval due to LDL cholesterol elevation and cardiovascular safety concerns.

Its trajectory illustrates why NASH drug development requires both efficacy AND cardiovascular safety to proceed  a particular challenge given that metabolic syndrome patients already carry elevated cardiovascular risk.

 

Is Resmetirom Available in India  What Should Indian Patients Do Now?

Resmetirom received FDA approval in March 2024 and is available in the United States. Its availability in India through the Central Drugs Standard Control Organisation (CDSCO) regulatory pathway is evolving, and patients should discuss current availability directly with their hepatologist.

What Is Available in Indian Clinical Practice Right Now?

For Indian NASH patients, the current evidence-supported management includes:

Structured weight loss through Mediterranean diet and 150 minutes per week of aerobic exercise  the most powerful single intervention available. 

GLP-1 agonists (semaglutide, liraglutide) where concurrent obesity or type 2 diabetes is present. Pioglitazone for NASH with type 2 diabetes and insulin resistance. 

Aggressive metabolic co-factor management  blood glucose, blood pressure, triglycerides, sleep apnoea assessment.

The key message for Indian patients: waiting for resmetirom to be widely available in India is not a strategy. The metabolic disease driving NASH progression does not pause while drug approvals proceed.

Why Fibrosis Staging Cannot Be Deferred?

The most important action for any Indian patient with known or suspected NASH is accurate fibrosis staging now  through FIB-4 calculation, FibroScan, or biopsy.

Knowing your fibrosis stage determines clinical urgency, treatment choices, and  when resmetirom becomes available  whether you fall within the eligible F2–F3 window.

For patients in Pune, this staging is available through liver disease specialist services at The Liver Transplant, where Dr. Bipin Vibhute provides comprehensive hepatology assessment including FibroScan and personalised management planning. 

A patient currently at F2 who defers staging for 2–3 years while “waiting for better drugs” may present at F3–F4 with narrowed treatment options.

If you have been diagnosed with NASH or significant fatty liver disease and want to understand your current fibrosis stage, treatment eligibility, and the management options available to you in Pune, Dr. Bipin Vibhute at thelivertransplant.com provides specialist hepatology and liver transplant assessment. Visit thelivertransplant.com to book your consultation today.

 

What Does NASH Treatment Look Like Right Now  Stage by Stage?

Treatment decisions in NASH are stage-dependent. Here is the current evidence-based framework:

F0–F1  Lifestyle Is the Primary Treatment

At early fibrosis stages, lifestyle modification  weight loss, diet, exercise  remains the most effective and most appropriate primary intervention. Pharmacological treatment is not routinely indicated at this stage.

For patients wanting practical, evidence-based guidance on what dietary and lifestyle changes actually look like in an Indian context, Lifestyle Changes and Diet for Preventing Fatty Liver Disease covers the specific food choices and activity patterns that drive liver fat reduction. 

Metabolic co-factors  diabetes, dyslipidemia, and hypertension should be aggressively managed.

F2–F3  Add Pharmacological Management

At moderate-to-advanced fibrosis, lifestyle remains essential, but pharmacological intervention is now appropriate. Where eligible, resmetirom is the first-line approved agent. GLP-1 agonists, pioglitazone, and SGLT2 inhibitors are the agents with the strongest evidence base currently available in India.

Bariatric surgery should be actively discussed in patients with obesity and F2–F3 fibrosis who have not achieved adequate weight loss  the liver outcomes from bariatric surgery at this stage are among the most durable in the field.

F4  Cirrhosis Management and Transplant Assessment

At cirrhosis, the management goal shifts from disease reversal to complication prevention. HCC surveillance (6-monthly ultrasound and AFP), variceal screening, nutrition optimisation, and transplant evaluation are the clinical priorities.

Final Thoughts

The approval of resmetirom is a genuine turning point  the first pharmacological agent ever specifically proven to reverse NASH activity and improve fibrosis in a randomised controlled trial.

It is not a cure. It is not for all patients. It requires concurrent lifestyle commitment. And for Indian patients, its availability is still evolving. But it represents proof that NASH is pharmacologically targetable and that more effective treatments are behind it.

The most urgent action for any NASH patient  regardless of drug availability  is accurate fibrosis staging. Knowing where you are determines what you can do, how urgently you need to act, and whether you will be eligible for the treatments that are coming.

Waiting and watching is only appropriate when you know what you are waiting for and that what you are watching is stable. Without staging, you have neither.

Frequently Asked Questions

What is the new approved drug for NASH in 2024? 

Resmetirom (brand name Rezdiffra) received FDA accelerated approval in March 2024  the first drug ever specifically approved for NASH. It is a thyroid hormone receptor beta agonist that improves hepatic fat metabolism and reduces liver inflammation and scarring. It is approved for adults with NASH and moderate-to-advanced fibrosis (F2 or F3 stages) alongside diet and exercise, and is not indicated for patients with cirrhosis (F4 fibrosis).

Can medication reverse NASH liver damage? 

Yes  in the right patients, at the right stage. Resmetirom achieved NASH resolution in approximately 30% of eligible patients and fibrosis improvement (reversal of scarring) in approximately 26% at 52 weeks in the MAESTRO-NASH trial. Weight loss of 10% or more produces similar outcomes through lifestyle alone. The critical factor is fibrosis stage  F2 and F3 fibrosis can be reversed, but established cirrhosis (F4) cannot be pharmacologically reversed.

Is resmetirom available in India? 

Resmetirom received FDA approval in the United States in March 2024. Its availability in India through the CDSCO regulatory pathway is evolving, and patients should discuss current status directly with their hepatologist. Indian patients with NASH should not defer treatment while awaiting availability  lifestyle modification, metabolic management, and currently available evidence-supported agents (GLP-1 agonists, pioglitazone) provide meaningful benefit while regulatory processes proceed.

Does semaglutide treat NASH or just help you lose weight? 

Semaglutide has direct beneficial effects on NASH beyond weight loss  the NASH phase 2b trial showed 59% NASH resolution (inflammatory activity reduction) compared to 17% on placebo. However, semaglutide did not achieve statistically significant fibrosis improvement in this trial. It is most appropriate for NASH patients with concurrent obesity or type 2 diabetes, where the combined metabolic and liver activity benefits are supported by evidence, while the larger phase 3 ESSENCE trial will clarify its full fibrosis impact.

What should I do while waiting for NASH medication to become available in India? 

Focus on what is available and proven now: 7–10% weight loss through Mediterranean diet and 150 minutes per week of exercise produces NASH resolution in approximately 40–50% of patients. Aggressive metabolic control (blood sugar, blood pressure, triglycerides) is non-negotiable. GLP-1 agonists and pioglitazone are available in India with evidence support. Most importantly, get your fibrosis accurately staged now  knowing whether you are at F2 or F3 determines urgency, available options, and future eligibility for resmetirom when it becomes widely available.